LON:AREC Arecor Therapeutics (AREC) Share Price, News & Analysis GBX 71.26 -1.24 (-1.71%) As of 12:11 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesNews and Trends About Arecor Therapeutics Stock (LON:AREC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arecor Therapeutics alerts:Sign Up Key Stats Today's Range 71.25▼ 7550-Day Range 57.50▼ 9052-Week Range 56▼ 95Volume10,012 shsAverage Volume24,914 shsMarket Capitalization£26.91 millionP/E Ratio71.26Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target. Read More Receive AREC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AREC Stock News HeadlinesArecor Therapeutics (LON:AREC) Releases Quarterly Earnings ResultsOctober 2, 2026 | americanbankingnews.comArecor Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2026September 30, 2026 | marketscreener.comMThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 7 at 1:00 AM | Chaikin Analytics (Ad)Arecor seeks £5.1m as insulin pump partnership talks reach term sheet stageSeptember 30, 2026 | uk.finance.yahoo.comEARNINGS: Arecor fundraise as loss widens; Northcoders' B2B progressSeptember 30, 2026 | lse.co.ukArecor Therapeutics to Raise GBP5 Million EquitySeptember 30, 2026 | marketscreener.comMArecor launches £5.13m share fundraising to drive next‑generation insulin developmentSeptember 30, 2026 | tipranks.comArecor's ultra-concentrated insulin holds ultra-rapid profile in peer-reviewed study - UPDATEAugust 13, 2026 | finance.yahoo.comSee More Headlines AREC Stock Analysis - Frequently Asked Questions How have AREC shares performed this year? Arecor Therapeutics' stock was trading at GBX 84.45 on January 1st, 2026. Since then, AREC shares have decreased by 11.2% and is now trading at GBX 75. How were Arecor Therapeutics' earnings last quarter? Arecor Therapeutics plc (LON:AREC) issued its quarterly earnings results on Thursday, October, 1st. The company reported ($8.00) earnings per share for the quarter. Arecor Therapeutics had a negative net margin of 200.00% and a positive trailing twelve-month return on equity of 3.75%. How do I buy shares of Arecor Therapeutics? Shares of AREC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Arecor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arecor Therapeutics investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Lowe's Companies (LOW) and SNDL (SNDL). Company Calendar Last Earnings10/01/2026Today10/07/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorEnergy Industry Oil, Gas & Consumable Fuels Sub-IndustryCoal & Consumable Fuels Current SymbolLON:AREC CIKN/A Webwww.americanresourcescorp.com Phone44 1223 426 060FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 1 Trailing P/E Ratio71.26 Forward P/E RatioN/A P/E GrowthN/ANet Income-£10.68 million Net Margins-200.00% Pretax MarginN/A Return on Equity3.75% Return on Assets-37.31% Debt Debt-to-Equity Ratio1.55 Current Ratio4.29 Quick Ratio6.24 Sales & Book Value Annual Sales£890 thousand Price / Sales30.23 Cash FlowGBX 14.05 per share Price / Cash Flow5.07 Book ValueGBX 16.58 per share Price / Book4.30Miscellaneous Outstanding Shares37,757,000Free FloatN/AMarket Cap£26.91 million OptionableNot Optionable Beta-0.18 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (LON:AREC) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
